Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18569094 | 1.00 | FUCA1 (0.33) | FUCA1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3590322 | 1.00 | FUCA1 (0.33) | FUCA1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL15547502 | 0.97 | FUCA1 (0.32) | FUCA1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23559839 | 0.84 | FUCA1 (0.37) | FUCA1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL15547392 | 0.80 | HTR2C (0.35) | FUCA1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| Trifluoroacetic Acid SCHEMBL21847051 | 0.80 | HTR2C (0.35) | FUCA1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL27572881 | 0.80 | — | — | |
| SCHEMBL2928744 | 0.79 | FUCA1 (0.31) | FUCA1 | |
| SCHEMBL24812981 | 0.79 | FUCA1 (0.31) | FUCA1 | |
| SCHEMBL30574698 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| WO-2019020657-A1 | PYRIDINE-3-SULFONAMIDE COMPOUNDS AS PI3-KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | WO | disclosed |
| US-9908890-B2 | Selective inhibitors of constitutive androstane receptor | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2018-03-06 | — | — | US | disclosed |
| US-9889130-B2 | Substituted 3-benzofuranyl-indol-2-one-3-acetamididopiperazine derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2018-02-13 | — | — | US | disclosed |
| EP-0861660-B9 | Curative medicine for disease caused by infection of Helicobacter | KANEKA CORP (JP) | 2006-06-28 | — | — | EP | disclosed |
| EP-0861660-B1 | Curative medicine for disease caused by infection of Helicobacter | KANEKA CORP (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-0787494-B1 | Use of rifamycin derivatives for the manufacture of a medicament for the treatment of diseases caused by infections of helicobacter pylori | KANEKA CORP (JP) | 2004-06-09 | — | — | EP | disclosed |
| EP-1305048-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | Wockhardt Limited (IN) | 2003-05-02 | — | — | EP | disclosed |
| US-20020177559-A1 | Quinolone derivatives | WOCKHARDT LIMITED | 2002-11-28 | — | — | US | disclosed |
| WO-2002009758-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | WOCKHARDT LIMITED (IN) | 2002-02-07 | — | — | WO | disclosed |
| US-5981522-A | ADMINISTERING RIFAMYCIN DERIVATIVE TO THE PATIENT TO TREAT GASTRITIS, GASTRODUODENITIS, EROSIVE GASTRITIS, GASTRIC EROSION, EROSIVE DUODENITIS, GASTRIC ULCER AND DUODENAL ULCER CAUSED BY HELICOBACTER PLORI | KANEKA CORPORATION (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0861660-A1 | Curative medicine for disease caused by infection of Helicobacter | KANEKA CORPORATION (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0787494-A1 | REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER | KANEKA CORPORATION (JP) | 1997-08-06 | — | — | EP | disclosed |
| US-4138566-A | Piperazinyl cyclobutenones | G. D. SEARLE & CO. (US) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | FUCA1 3717/4885CHRNB2 4875/4885CHRNB4 4872/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | FUCA1 3717/4885CHRNB2 4875/4885CHRNB4 4872/4885 |
| US-20020177559-A1 | Quinolone derivatives | ABCB11, ABCB1, ABCG2 | FUCA1 1870/4885CHRNB2 4288/4885CHRNB4 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.